ReviewPsychiatry and clinical neurosciences2026
The development of positron emission tomography (PET) tracer for glutamate AMPA receptors and its application to human biology and clinics.
Review in Psychiatry and clinical neurosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Psychiatric and neurological disorders severely compromised patients' quality of life. Despite their urgent needs, the development of diagnostics and therapeutics based on the biological basis has made only little progress. This is due to limited evidence on the biological basis of these disorders in humans. Synapses are fundamental structural units of neurotransmission, and neuropsychiatric disorders are considered as 'synapse diseases'. Thus, a translational approach based on synaptic physiology is important to understand these disorders. Excitatory glutamatergic synapses play principal roles in neuronal functions. Glutamate α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) is a fundamental molecule of glutamatergic neurotransmission and therefore is considered to be a promising translational target. Here we review the limitations of current diagnostics and therapeutics of psychiatric disorders and claim the essential need for the promotion of translational medicine based on the synaptic physiology of AMPAR. Further, we introduce our recent translational challenge to tackle these diseases by targeting AMPARs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.